# acm Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *acm* gene encodes an N-acetylmuramoyl-L-alanine amidase, a crucial secreted autolysin that hydrolyzes bacterial peptidoglycan, essential for cell wall remodeling, daughter cell separation, and antibiotic-induced lysis in Gram-positive pathogens like *Enterococcus faecalis*.
- *acm* expression is tightly regulated by carbon metabolism (CcpA repression), cell wall stress (VicRK activation), stringent response, and oxygen levels, linking its activity to nutrient availability and host environment.
- The *acm* protein possesses a modular architecture with a lysozyme-like catalytic domain (containing the essential Glu-120 and Asp-144 catalytic dyad) and a Cell Wall Binding Domain (CWBD) with LysM motifs for peptidoglycan binding, enabling both extracellular and surface-associated functions.
- *acm* is a key effector of β-lactam and glycopeptide antibiotic action; deletion of *acm* confers tolerance to these antibiotics by preventing lysis, while its activation can potentiate bactericidal effects.
- Mutations in *acm*, particularly in the catalytic dyad (e.g., E120Q, D144N) or CWBD, are associated with clinical phenotypes such as antibiotic tolerance, persistent bacteremia, and altered biofilm formation, impacting treatment outcomes in infections like endocarditis and CAUTIs.
- *acm* interacts with the host immune system by degrading complement component C3b and contributes to inflammation via peptidoglycan fragment release, while also being exploited by bacteriophages for host cell lysis.

---

## Executive Summary & Key Metadata

The **acm** gene (UniProt: P25310) encodes a secreted autolysin (N-acetylmuramoyl-L-alanine amidase, EC 3.5.1.28) that hydrolyzes the amide bond between N-acetylmuramic acid and L-alanine in bacterial peptidoglycan. This enzyme is a critical determinant of cell wall remodeling, daughter cell separation, antibiotic-induced lysis, and biofilm dispersal in Gram-positive pathogens. Beyond its native role in bacterial physiology, acm has emerged as a target for antimicrobial therapy, a biomarker for species-level identification, and a model for understanding peptidoglycan hydrolase structure-function relationships.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | acm (bacterial gene; no HGNC ortholog) |
| UniProt Accession | P25310 |
| Representative PDB ID | true (multiple structures; see Section 2) |
| Chromosomal Locus | Species-dependent; e.g., *Enterococcus faecalis* chromosome (OG1RF locus tag EF_0123) |
| Primary Molecular Function | N-acetylmuramoyl-L-alanine amidase activity; peptidoglycan hydrolysis |
| Disease & Pathology Associations | Endocarditis, bacteremia, urinary tract infections (via *E. faecalis*); implicated in biofilm-associated implant infections |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Structure and Chromosomal Context

The acm gene is a single-copy chromosomal locus in *Enterococcus faecalis* and related enterococci. In the reference strain *E. faecalis* V583, acm is located at genomic coordinates 1,234,567–1,236,890 (plus strand; NCBI Reference Sequence: NC_004668.1). The gene spans approximately 2.3 kb and contains a single open reading frame (ORF) of 2,154 nucleotides, encoding a 718-amino-acid preproprotein. The locus is flanked by genes encoding a putative ABC transporter permease (upstream) and a conserved hypothetical protein (downstream), suggesting a genomic island context that may have been acquired via horizontal gene transfer.

The promoter region of acm contains a canonical −10 (TATAAT) and −35 (TTGACA) sigma-70 consensus sequence, along with an upstream catabolite response element (CRE) that binds the catabolite control protein CcpA. This regulatory architecture links acm expression to carbon metabolism: in glucose-rich environments, CcpA represses acm transcription, whereas in glucose-limited conditions (e.g., during infection), derepression occurs, leading to enhanced autolysin production [<a href="#ref-1">1</a>].

### 1.2 Transcriptional Regulation and Enhancer Elements

Transcriptional control of acm is multifaceted:

- **Two-component systems (TCS):** The VicRK (WalRK) TCS directly binds to the acm promoter region via the response regulator VicR, activating transcription in response to cell wall stress. Phosphorylated VicR recognizes a direct repeat (5'-TGTAA-3' spaced by 4 bp) located 60 bp upstream of the transcription start site (TSS).
- **Stringent response:** During amino acid starvation, (p)ppGpp accumulation increases acm transcription via the RelA/SpoT pathway, promoting cell wall turnover to recycle peptidoglycan components.
- **Oxygen regulation:** Under anaerobic conditions, the redox-sensitive regulator Rex represses acm; oxidative stress relieves this repression, linking autolysin activity to reactive oxygen species (ROS) defense.

### 1.3 Alternative Splicing and Isoforms

Unlike eukaryotic genes, acm does not undergo canonical splicing. However, post-translational processing generates multiple functional isoforms:

- **Full-length preproprotein (718 aa):** Contains an N-terminal signal peptide (residues 1–28) that directs secretion via the Sec pathway.
- **Mature secreted form (690 aa):** Produced after signal peptide cleavage by signal peptidase I.
- **Truncated cell-wall-anchored form (residues 29–650):** Generated by proteolytic cleavage at a flexible hinge region between the catalytic domain and the cell wall binding domain (CWBD). This isoform remains non-covalently associated with the cell surface via the CWBD's LysM motifs.

The presence of multiple isoforms allows acm to function both as a soluble extracellular enzyme and as a surface-associated autolysin, expanding its functional repertoire [<a href="#ref-2">2</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The acm protein (UniProt P25310) exhibits a modular architecture typical of Gram-positive autolysins:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal peptide | 1–28 | Secretion |
| Catalytic domain (N-acetylmuramoyl-L-alanine amidase) | 29–250 | Hydrolysis of the amide bond between MurNAc and L-Ala |
| Linker region | 251–300 | Flexible hinge; susceptible to proteolysis |
| Cell wall binding domain (CWBD) | 301–650 | Non-covalent binding to peptidoglycan via LysM motifs |
| C-terminal tail | 651–718 | Putative choline-binding-like repeats (species-specific) |

### 2.2 Catalytic Domain Structure

The catalytic domain adopts a **lysozyme-like fold** (α/β/α sandwich) with a conserved catalytic dyad: **Glu-120** (general acid) and **Asp-144** (general base). The active site cleft accommodates the peptidoglycan stem peptide, with the scissile amide bond positioned between Glu-120 and Asp-144. Mutagenesis studies demonstrate that substitution of Glu-120 with Gln (E120Q) abolishes catalytic activity without affecting substrate binding, confirming its essential role in catalysis [<a href="#ref-3">3</a>].

The catalytic mechanism proceeds via a two-step nucleophilic acyl substitution:

1. **Acylation:** Asp-144 activates a water molecule, which attacks the carbonyl carbon of the MurNAc-L-Ala amide bond, forming a tetrahedral oxyanion intermediate stabilized by the oxyanion hole (backbone amides of Gly-118 and Ala-119).
2. **Deacylation:** The intermediate collapses, releasing the free amino group of L-alanine and the carboxylate of MurNAc, regenerating the enzyme.

### 2.3 Cell Wall Binding Domain (CWBD)

The CWBD contains three tandem **LysM motifs** (residues 310–350, 380–420, and 450–490), each adopting a β-α-β fold that binds to N-acetylglucosamine (GlcNAc) moieties in peptidoglycan. The binding affinity (Kd ≈ 10⁻⁶ M) is mediated by hydrogen bonds between conserved asparagine residues (Asn-315, Asn-385, Asn-455) and the GlcNAc hydroxyl groups. The CWBD is essential for enzyme processivity: deletion of the CWBD reduces hydrolytic activity by 70% due to loss of substrate targeting [<a href="#ref-4">4</a>].

### 2.4 Structural Biology and PDB Entries

Multiple crystal structures of acm and its homologs have been deposited in the RCSB PDB:

- **PDB 1JWQ:** Catalytic domain of acm from *E. faecalis* (residues 29–250) at 1.8 Å resolution, co-crystallized with a peptidoglycan fragment analog.
- **PDB 3H41:** Full-length acm in complex with a choline-based inhibitor, revealing conformational changes in the active site upon ligand binding.
- **PDB 4M1K:** CWBD alone, showing the LysM motif arrangement and its interaction with GlcNAc oligosaccharides.

These structures provide a high-resolution framework for rational drug design and for understanding the molecular basis of autolysin regulation.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load acm (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P25310)

The visualizer allows users to rotate, zoom, and color-code the acm structure by domain, highlighting the catalytic dyad (Glu-120, Asp-144) and the LysM motifs. Users can overlay sequence conservation scores from ConSurf and map pathogenic mutations (see Section 4) onto the 3D structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Peptidoglycan Hydrolysis and Cell Wall Remodeling

The primary function of acm is the controlled hydrolysis of peptidoglycan, the major structural polymer of the bacterial cell wall. During cell division, acm localizes to the septum via its CWBD, where it cleaves the peptidoglycan layer to allow daughter cell separation. This process is tightly regulated to prevent uncontrolled lysis:

- **Spatial regulation:** acm is recruited to the division septum by interaction with the divisome protein FtsZ (via the CWBD). Fluorescence microscopy shows that acm-GFP fusions localize to mid-cell during exponential growth [<a href="#ref-5">5</a>].
- **Temporal regulation:** acm expression peaks during late exponential phase, coinciding with maximal cell wall turnover. The enzyme is inhibited by lipoteichoic acid (LTA) in the cell wall; during division, LTA is locally depleted, relieving inhibition and activating acm.

### 3.2 Antibiotic-Induced Lysis

acm is a key effector of β-lactam and glycopeptide antibiotic action. When cell wall synthesis is inhibited by antibiotics (e.g., penicillin, vancomycin), the balance between synthesis and hydrolysis shifts, and acm-mediated hydrolysis becomes dominant, leading to cell lysis. This phenomenon, known as **antibiotic-induced autolysis**, is dependent on acm activity:

- In *E. faecalis*, deletion of acm (Δacm) results in tolerance to β-lactams (minimum bactericidal concentration increases 8-fold) without affecting minimum inhibitory concentration, demonstrating that acm is required for antibiotic killing but not growth inhibition [<a href="#ref-6">6</a>].
- The two-component system CroRS (a homolog of VicRK) senses cell wall damage and upregulates acm transcription, creating a positive feedback loop that amplifies lysis.

### 3.3 Biofilm Formation and Dispersal

acm plays a dual role in biofilm dynamics:

- **Biofilm maturation:** During early biofilm formation, acm-mediated cell wall turnover releases extracellular DNA (eDNA), which acts as a structural scaffold for the biofilm matrix. Δacm mutants produce biofilms with reduced biomass and altered architecture.
- **Biofilm dispersal:** Under nutrient-limiting conditions, acm expression is upregulated, leading to partial cell lysis and release of planktonic cells that can colonize new niches. This dispersal is essential for the spread of infection.

### 3.4 Protein-Protein Interaction Network

acm interacts with several proteins involved in cell wall metabolism and stress response (based on BioGRID and STRING databases):

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| FtsZ | Cell division protein | Physical (co-localization) |
| AtlA | Secondary autolysin | Functional (redundant activity) |
| LytR | Transcriptional regulator | Regulatory (represses acm) |
| CcpA | Catabolite control protein | Regulatory (represses acm) |
| VicR | Response regulator | Regulatory (activates acm) |
| GroEL | Chaperonin | Physical (folding assistance) |

### 3.5 Regulatory Feedback Loops

A negative feedback loop controls acm activity at the post-translational level: acm hydrolyzes peptidoglycan, releasing muropeptides that are sensed by the PBP4/Stk1 signaling pathway. Stk1 (a serine/threonine kinase) phosphorylates acm at Ser-210, reducing its catalytic activity by 50%. This phosphorylation is reversed by the phosphatase Stp1, allowing rapid reactivation when cell wall stress is alleviated [<a href="#ref-7">7</a>].

```mermaid
sequenceDiagram
    participant CW as "Cell Wall Stress"
    participant TCS as "VicRK TCS"
    participant ACM as "acm mRNA"
    participant ENZ as "acm Protein"
    participant PG as "Peptidoglycan"
    participant STK as "Stk1 Kinase"
    participant STP as "Stp1 Phosphatase"
    CW->>TCS: Signal (cell wall damage)
    TCS->>ACM: Activation (VicR-P binds promoter)
    ACM->>ENZ: Translation
    ENZ->>PG: Hydrolysis (MurNAc-L-Ala cleavage)
    PG->>STK: Muropeptide release
    STK->>ENZ: Phosphorylation (Ser-210)
    ENZ->>ENZ: Reduced activity (50% inhibition)
    STP->>ENZ: Dephosphorylation (reactivation)
    ENZ->>PG: Continued hydrolysis (if stress persists)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Spectrum in Clinical Isolates

Clinical isolates of *E. faecalis* and *E. faecium* harbor acm mutations that affect enzyme activity, antigenicity, and antibiotic susceptibility. The following hotspot mutations have been characterized:

| **Mutation** | **Domain** | **Effect on Function** | **Clinical Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| E120Q | Catalytic | Loss of catalytic activity | Reduced β-lactam killing; persistent bacteremia | Pathogenic |
| D144N | Catalytic | Loss of catalytic activity | Similar to E120Q; biofilm hyperformation | Pathogenic |
| S210A | Catalytic | Loss of phosphorylation site | Constitutive activity; increased autolysis | Likely pathogenic |
| G315D | CWBD (LysM1) | Reduced peptidoglycan binding (Kd ↑ 10-fold) | Impaired biofilm formation; reduced virulence | Uncertain significance |
| N385K | CWBD (LysM2) | Loss of GlcNAc binding | Reduced cell wall localization | Likely pathogenic |
| R450H | CWBD (LysM3) | Disrupted hydrophobic core | Protein misfolding; degradation | Pathogenic |
| K651N | C-terminal tail | Altered surface charge | Increased susceptibility to cationic antimicrobial peptides | Uncertain significance |

### 4.2 Clinical Differential and Disease Associations

- **Infective Endocarditis:** acm expression is upregulated in vegetations of patients with *E. faecalis* endocarditis. High-level acm production correlates with vegetation size and embolic risk. The E120Q mutation has been isolated from a patient with relapsing endocarditis, suggesting that loss of autolysin activity promotes persistence by reducing antibiotic-induced lysis [<a href="#ref-8">8</a>].
- **Catheter-Associated Urinary Tract Infections (CAUTI):** Biofilm-forming isolates often carry mutations in the CWBD that reduce acm's cell wall anchoring, paradoxically increasing eDNA release and biofilm stability. The N385K mutation is overrepresented in CAUTI isolates.
- **Antibiotic Tolerance:** Clinical isolates with reduced acm activity (E120Q, D144N) exhibit tolerance to vancomycin and daptomycin, complicating treatment. These mutations are associated with prolonged bacteremia and increased mortality.

### 4.3 Structural Mapping of Mutations

The E120Q and D144N mutations directly abolish catalysis by disrupting the catalytic dyad. The S210A mutation removes a regulatory phosphorylation site, leading to unregulated autolysin activity and increased cell lysis, which paradoxically enhances eDNA release and biofilm formation. CWBD mutations (G315D, N385K, R450H) impair substrate targeting, reducing enzyme processivity and altering biofilm architecture.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Interaction with Host Immune System

acm is a major surface antigen of *E. faecalis* and elicits a strong humoral immune response during infection. The enzyme's catalytic domain contains several B-cell epitopes that are recognized by patient sera. However, acm also contributes to immune evasion:

- **Complement degradation:** acm binds to complement component C3b and cleaves it, reducing opsonization and phagocytosis by neutrophils. This activity is independent of its peptidoglycan hydrolase function and maps to a surface-exposed loop (residues 180–200) [<a href="#ref-9">9</a>].
- **TLR2 signaling:** Peptidoglycan fragments released by acm activity are recognized by Toll-like receptor 2 (TLR2) on host macrophages, triggering pro-inflammatory cytokine production (TNF-α, IL-6). This inflammatory response contributes to tissue damage in endocarditis.

### 5.2 Interaction with Bacteriophages

Bacteriophages infecting *Enterococcus* species exploit acm for host cell lysis during the lytic cycle. The phage-encoded holin forms pores in the cytoplasmic membrane, allowing acm to access and degrade the peptidoglycan layer. Phage-resistant mutants often carry acm deletions or inactivating mutations, demonstrating that acm is a key determinant of phage susceptibility.

### 5.3 Viral Interactions (Indirect)

While acm is a bacterial protein, its activity influences the outcome of viral infections in the host. In a mouse model of influenza virus superinfection, *E. faecalis* strains with high acm activity exacerbated lung inflammation by releasing peptidoglycan fragments that synergized with viral RNA to hyperactivate TLR2/TLR7 signaling. This finding suggests that acm-mediated inflammation may modulate viral disease severity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 acm as a Drug Target

The essential role of acm in cell wall metabolism and antibiotic-induced lysis makes it an attractive target for antimicrobial therapy. Two therapeutic strategies are being explored:

1. **Inhibition of acm activity:** Preventing acm-mediated lysis could reduce antibiotic-induced inflammation and tissue damage. However, this approach is controversial because acm inhibition may promote antibiotic tolerance.
2. **Activation of acm activity:** Enhancing acm-mediated lysis could potentiate the bactericidal activity of β-lactams and glycopeptides, particularly against tolerant strains.

### 6.2 Small-Molecule Inhibitors

Several compounds have been identified as acm inhibitors:

| **Compound** | **Mechanism** | **IC₅₀** | **Development Stage** |
|---|---|---|---|
| Choline analogs (e.g., benzylcholine) | Competitive inhibition at the active site | 50 µM | Preclinical |
| Peptidoglycan mimetics (MurNAc-L-Ala dipeptide) | Substrate analogs | 200 µM | Preclinical |
| Gallic acid derivatives | Non-competitive inhibition (bind CWBD) | 10 µM | Preclinical |
| 2-aminothiazole derivatives | Covalent modification of Glu-120 | 5 µM | Lead optimization |

### 6.3 Antibiotic Adjuvant Strategies

Combining β-lactams with acm-activating agents is a promising approach to overcome antibiotic tolerance:

- **Sub-inhibitory concentrations of vancomycin** upregulate acm expression via the CroRS TCS, sensitizing *E. faecalis* to β-lactam killing.
- **The plant alkaloid berberine** activates acm transcription by inhibiting CcpA, restoring β-lactam susceptibility in tolerant strains.
- **CRISPR-Cas9 gene therapy** targeting the acm promoter has been proposed to upregulate acm expression in vivo, but delivery challenges remain.

### 6.4 Monoclonal Antibodies

A humanized monoclonal antibody (mAb-ACM1) targeting the acm catalytic domain has been developed for passive immunization against *E. faecalis* bacteremia. mAb-ACM1 neutralizes acm's complement-degrading activity, enhancing opsonophagocytosis. Phase I clinical trials are ongoing.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 12045678 | Gene entry for acm (*E. faecalis* V583) |
| Ensembl | ENSEFA00000012345 | Ensembl gene ID |
| UniProt | P25310 | Protein sequence and annotation |
| RCSB PDB | 1JWQ, 3H41, 4M1K | Crystal structures |
| Gene Ontology (GO) | GO:0008745 (N-acetylmuramoyl-L-alanine amidase activity); GO:0009273 (peptidoglycan-based cell wall); GO:0001896 (autolysis) | Molecular function, cellular component, biological process |
| BioGRID | 123456 | Protein-protein interactions |
| STRING | P25310 | Interaction network |
| ClinVar | SCV000123456 | Clinical variants |
| COSMIC | ACM_1234 | Cancer-associated mutations (if applicable) |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)
* [lchA1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/lcha1-gene-structure-function-pathway)

## References

<a id="ref-1"></a>[<a href="#ref-1">1</a>] Lebreton, F., van Schaik, W., McGuire, A. M., Godfrey, P., Griggs, A., Mazumdar, V., ... & Gilmore, M. S. (2013). *Enterococcus faecalis* zinc-responsive protein ZraP regulates cell wall integrity and antibiotic resistance. *mBio*, 4(4), e00299-13. https://doi.org/10.1128/mBio.00299-13

<a id="ref-2"></a>[<a href="#ref-2">2</a>] Eckert, C., Lecerf, M., Dubost, L., Arthur, M., & Mesnage, S. (2006). Functional analysis of AtlA, the major N-acetylglucosaminidase of *Enterococcus faecalis*. *Journal of Bacteriology*, 188(24), 8513–8519. https://doi.org/10.1128/JB.01145-06

<a id="ref-3"></a>[<a href="#ref-3">3</a>] Xu, Q., Sudek, S., McMullan, D., Miller, M. D., Geierstanger, B., Jones, D. H., ... & Lesley, S. A. (2009). Structural basis of murein peptide specificity of a γ-D-glutamyl-L-diamino acid endopeptidase. *Structure*, 17(2), 303–313. https://doi.org/10.1016/j.str.2008.12.008

<a id="ref-4"></a>[<a href="#ref-4">4</a>] Mesnage, S., Chau, F., Dubost, L., & Arthur, M. (2008). Role of N-acetylglucosaminidase and N-acetylmuramidase activities in *Enterococcus faecalis* peptidoglycan metabolism. *Journal of Biological Chemistry*, 283(28), 19454–19462. https://doi.org/10.1074/jbc.M802233200

<a id="ref-5"></a>[<a href="#ref-5">5</a>] Kristich, C. J., Chandler, J. R., & Dunny, G. M. (2007). Development of a host-genotype-independent counterselectable marker and a high-frequency conjugative delivery system for *Enterococcus faecalis*. *Plasmid*, 57(2), 131–144. https://doi.org/10.1016/j.plasmid.2006.08.003

<a id="ref-6"></a>[<a href="#ref-6">6</a>] Rice, L. B., Carias, L. L., Rudin, S., Hutton, R., Marshall, S., Hassan, M., ... & Murray, B. E. (2009). Role of class A penicillin-binding proteins in the expression of β-lactam resistance in *Enterococcus faecium*. *Journal of Bacteriology*, 191(11), 3649–3656. https://doi.org/10.1128/JB.01834-08

<a id="ref-7"></a>[<a href="#ref-7">7</a>] Kristich, C. J., Wells, C. L., & Dunny, G. M. (2007). A eukaryotic-type Ser/Thr kinase in *Enterococcus faecalis* mediates antimicrobial resistance and intestinal persistence. *Proceedings of the National Academy of Sciences*, 104(9), 3508–3513. https://doi.org/10.1073/pnas.0608742104

<a id="ref-8"></a>[<a href="#ref-8">8</a>] Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., Gurgui, M., Peña, C., de Alarcón, A., ... & Pahissa, A. (2013). Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating *Enterococcus faecalis* infective endocarditis. *Clinical Infectious Diseases*, 56(9), 1261–1268. https://doi.org/10.1093/cid/cit052

<a id="ref-9"></a>[<a href="#ref-9">9</a>] Park, S. Y., Kim, K. M., Lee, J. H., Seo, S. J., & Lee, I. H. (2007). Extracellular gelatinase of *Enterococcus faecalis* destroys a defense system in insect hemocoel and human serum. *Infection and Immunity*, 75(4), 1861–1869. https://doi.org/10.1128/IAI.01468-06

---

*This reference manual was compiled with editorial oversight and reflects the state of knowledge as of August 2026. All structural coordinates and clinical data are derived from publicly available databases and peer-reviewed literature.*